Navigation Links
MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
Date:2/16/2011

MINNETONKA, Minn., Feb. 8, 2011 /PRNewswire/ -- MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce the latest release of ENLIGHTEN®, the company's flagship eClinical solution.  The ENLIGHTEN system, which provides a proven, highly configurable, and easy-to-use electronic data capture (EDC) and clinical trial management system (CTMS), has effectively supported the world-wide clinical research needs of pharmaceutical and medical device companies for over 10 years.

The latest ENLIGHTEN release contains numerous enhancements which fall into three major categories: 1) expanded reporting capabilities that provide users with superior report creation flexibility and increased data visibility, 2) increased configurability to more quickly and easily meet customers' unique, study-specific requirements, and 3) optimized system performance to ensure rapid system response times and a superior user experience.

"For over a decade, ENLIGHTEN has successfully supported clinical studies of all types – from large to small, from early phase trials to post market registries, and across virtually every therapeutic area," remarked Al Sherwood, MedNet's Senior Vice President of Research and Development and co-founder of MedNet Solutions. "Proof of ENLIGHTEN's success is MedNet's exceptionally high level of repeat customer business.  But we're not resting on our laurels…we're committed to continuing to enhance our systems to better meet our customers' evolving needs."

"The last thing a sponsor should have to worry about is their EDC partner," stated John M. (Rob) Robertson, President and CEO of MedNet Solutions.  "And with MedNet, there's no need to worry. From our proven systems to our experienced, hardworking, and responsive staff, MedNet is the eClinical company our customers know they can rely on and trust."

For more information on MedNet Solutions and the ENLIGHTEN EDC / eClinical solution, or to schedule a product demonstration, please call MedNet Solutions at (866) 258-2735, email MedNet at contact@mednetstudy.com, or visit www.mednetstudy.com.

About MedNet SolutionsMedNet Solutions is a leading healthcare technology company specializing in clinical study management systems designed for the global life sciences market. Applying critical insight, proven technology and unwavering support, MedNet delivers powerful, flexible and easy-to-use web-based solutions that support our customers' clinical studies, registries and investigator initiated trials. Since 2000, MedNet has successfully supported leading pharmaceutical, medical device, and biotechnology organizations on projects spanning 6 continents and more than 40 countries. MedNet delivers a superior customer experience from beginning to end.  For more information, please visit www.mednetstudy.com. Contact Information:Dirk H. NelsonMarketing Manager110 Cheshire Lane, Suite 300Minnetonka, MN  55305USA(763) 258-2735
'/>"/>

SOURCE MedNet Solutions
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
2. MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse
3. MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse
4. Loss of oyster reefs a global problem, but one with solutions
5. Researchers discover potential solutions to New England roadside erosion
6. New research contains solutions to common pear disease
7. Patriot Data Solutions Group Selected to Assist Louisiana District Attorney Association with Pilot Project
8. CIC Announces Upcoming Webinar: Business Challenges & Technology Solutions in 2011: What Leading Insurance Carriers are Planning Now; eSignature Implications
9. Naval Science and Technology Conference to highlight solutions to warfighter challenges
10. Motorola Solutions Introduces Industrys Most Comprehensive Enterprise Device Management Platform
11. Industry to Demonstrate Off-the-Shelf Integrated Force Protection and Counter-Terrorism Solutions at Northern Virginia Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: